Clinical trials: Head and Neck Squamous Cell Carcinomas
Sentinel Lymph Node, Head and Neck Squamous Cell Carcinoma
Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC
Head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Cervical lymph node metastasis is frequently encounted on the date of diagnosis.
- Trial name
- NCT05437380
- Testing
- peritumoral microbubbles and contrast-enhanced ultrasonography
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Circulating Tumor Cell, HNSCC
Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer
Cancer has been a significant cause of human death in the recent two decades, although detection, diagnosis, and cancer treatments improved and evolved rapidly.
- Trial name
- NCT06755762
- Testing
- Organoid 3D culture
- Where
- Taiwan
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Esophageal Squamous Cell Carcinoma
Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction
A single-institution, randomize controlled trial is to be held to evaluate the correlation between blood supply in the gastic conduit and the incidence of anastomotic fistula during radical operation for esophageal squamous cell…
- Trial name
- NCT04229524
- Testing
- Fluorescence angiography
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
Locally Advanced Malignant Neoplasm
Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
The benefit of induction chemotherapy followed by chemoradiotherapy for locally advanced head and neck squamous cell carcinoma is unknown. The present study is investigating if this therapeutic strategy improve overall survival.
- Trial name
- INDUCTION (NCT03815903)
- Testing
- Induction chemotherapy, Chemoradiotherapy
- Where
- Brazil
- Volunteers
- 434 people
- Sponsor
- Barretos Cancer Hospital
HEAD & NECK Cancer
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
The purpose of this study is to test the safety of RAD001 (everolimus) tablets at different dose levels, when added to docetaxel and cisplatin.
- Trial name
- NCT00935961
- Testing
- RAD001 + docetaxel + cisplatin
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma
Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC
The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1 in patients with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT02999646
- Testing
- MVX-ONCO-1
- Where
- 4 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- Maxivax SA
Squamous Cell Carcinoma of the Head and Neck
Hyperbaric Radiation Sensitization of Head and Neck Cancers
There is reason to believe that hyperbaric oxygen administered immediately prior to radiotherapy will prove beneficial for this cancer type and stage.
- Trial name
- NCT03843671
- Testing
- Hyperbaric oxygen, Hyperbaric chamber
- Where
- 5 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- National Baromedical Services
Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
This is a Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck, Metastasis, Recurrence
- Trial name
- NCT03799744
- Testing
- VCN-01, Durvalumab
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Institut Català d'Oncologia
Head and Neck Squamous Cell Carcinoma
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
In phase I of the trial, the investigators aim to explore the safety and feasibility of abemaciclib in combination with nivolumab in patients with recurrent/metatstatic head and neck squamous cell carcinoma (RM-HNSCC).
- Trial name
- NCT03655444
- Testing
- Abemaciclib, Nivolumab, Tumor biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer
Treatment Selection According to Skin Reaction to Cetuximab
The therapy of patients with locally advanced head and neck cancer will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e.
- Trial name
- NCT01472653
- Testing
- cisplatin, radiotherapy, cetuximab
- Where
- Slovenia
- Volunteers
- 120 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
This phase I trial studies the side effects and best dose of TLR8 Agonist VTX-2337 when given together with cetuximab in treating patients with locally advanced, recurrent, or metastatic squamous cell cancer of the head and neck…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01334177
- Testing
- TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Head and Neck Cancer
Detection in Peripheral Blood of Circulating Tumor Cells in Patient With Head and Neck Squamous Cell Carcinoma
The dissemination of individual tumor cells is a common phenomenon in solid cancers. Detection of tumor cells in peripheral blood circulating tumor cells (CTC) in nonmetastatic situation is of high prognostic significance.
- Trial name
- CTCVADS (NCT02892786)
- Testing
- Circulating Tumor Cells
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut de Cancérologie de Lorraine
Squamous Cell Carcinoma of the Head and Neck
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
A multicentre, open-label, non-randomized, phase Ib neoadjuvant study of intravenous NG-641, as monotherapy or in combination with pembrolizumab, in patients with surgically resectable squamous cell carcinoma of the head and neck…
- Trial name
- MOAT (NCT04830592)
- Testing
- NG-641, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Akamis Bio
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study.
- Trial name
- OASIS (NCT04503967)
- Testing
- Anlotinib Hydrochloride With Nivolumab
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
Head and Neck Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase I trial to study the effectiveness of docetaxel plus radiation therapy in treating patients who have stage III or stage IV head and neck cancer.
- Trial name
- NCT00006107
- Testing
- Taxotere, Surgery, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma of the Head and Neck
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck
This research study is for subjects with squamous cell cancer of the head and neck which is not solely treatable with surgery or radiation.
- Trial name
- NCT00184028
- Testing
- Taxotere, Oxaliplatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Southern California
Squamous Cell Carcinoma of the Head and Neck
Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This study will accrue in two "phases". During the first "phase" of the study, the optimal dose of temsirolimus in combination with cisplatin and cetuximab will be determined.
- Trial name
- NCT01015664
- Testing
- temsirolimus, cisplatin, cetuximab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Tennessee Cancer Institute
Esophageal Cancer
Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00008047
- Testing
- fluorouracil, hydroxyurea, paclitaxel
- Where
- 14 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.